1 / 19

Innovations in Management of Cardiovascular Disease for Global Health

Innovations in Management of Cardiovascular Disease for Global Health. Elsayed Z. Soliman MD, MSc, MS Epidemiological Cardiology Research Center (EPICARE) Wake Forest School of Medicine, Winston Salem, NC. 2011 Global Health Conference- Montreal, Canada November 13, 2011. Outline.

monty
Download Presentation

Innovations in Management of Cardiovascular Disease for Global Health

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Innovations in Management of Cardiovascular Disease for Global Health Elsayed Z. Soliman MD, MSc, MS Epidemiological Cardiology Research Center (EPICARE) Wake Forest School of Medicine, Winston Salem, NC 2011 Global Health Conference- Montreal, Canada November 13, 2011

  2. Outline • Global burden of CVD • Paradigm shift in concepts • Public health approach vs. high risk strategy • Individual vs. global (total) CVD risk assessment/management • Applications • WHO/ISH risk prediction charts • Polypill

  3. Distribution of major causes of death WHO 2011

  4. Global burden of CVD • 17.3 million people died from CVDs in 2008 • 80% of CVD deaths take place in low- and middle-income countries • 23.6 million expected to die from CVD By 2030 WHO 2011

  5. Meeting the challenge Life saving interventions are available, but the challenge is to increase its use by enhancing: • Availability • Affordability • Adherence • Sustainability A paradigm shift in concepts is needed!!!

  6. Public health approach vs. high risk strategy Prevention paradox: “An intervention which brings much benefit to population brings little benefit to individual and inversely” Rose G. 1995

  7. High Risk Strategy Population Strategy ... WHO publications

  8. Global risk assessment • An assessment of total (global) risk based on the sum of all major CVD risk factors can be useful for: (1) Identification of high-risk patients who deserve immediate attention and intervention (2) Motivation of patients to adhere to risk-reduction therapies (3) Modification of intensity of risk-reduction efforts based on the total risk estimate Grundy et al. Circulation doi: 10.1161/01.CIR.100.13.1481

  9. Global risk assessment: WHO CVD risk predication charts • Indicates total 10-year risk of a fatal or non-fatal CVD events, based on: age, sex, blood pressure, presence or absence of diabetes, smoking status, and cholesterol level (if available) • Geographic region-specific

  10. Global vs. individual CVD risk management Source: Global Health Risks: Mortality and burden of disease attributable to selected major risks. WHO 2009

  11. Global vs. individual CVD risk management Neaton JD et al Arch Intern Med. 1992;152:56-64

  12. Global risk managementPolypill • A combination of multiple CVD drugs in one pill • Proponents: • Tackles multiple risk CVD factors • Addresses adherence • Expected to be inexpensive • Opponents: • Concerns about individualized medicine • Negative impact on lifestyle BMJ 206:141903;32

  13. Global risk managementPolypill • Wald and Law proposed Polypill strategy • Combination of statin, thiazide diuretic, β blocker, ACE-I, folic acid and aspirin • To be given to everyone above the age of 55 years • No need for risk factor monitoring • 88% estimated reduction in CHD and 80% in stroke • Current Polypill strategies: • Exclude folic acid • Not for everyone • Estimated effect on risk reduction is less than that of Wald and Law

  14. Polypill efficacyTIPS- Indian Polycap Indian Polycap Study (TIPS) investigators. Lancet 2009;373:1341–1351.

  15. Polypill acceptabilityWHO-sponsored Sri-Lanka pilot study • Patient acceptability • 203 patients who completed the study and 207 who were screened but deemed ineligible to be enrolled • Approx. 90% of the patients who completed the study indicated that they would "definitely" or "probably" take the pill for life if it were shown to be effective in reducing CVD risk • A similar response level (89%) was obtained from those who were screened but found to be ineligible for the study Soliman et al (Trials 2011).

  16. Polypill acceptabilityWHO-sponsored Sri-Lanka pilot study • Physician acceptability • 84 physicians from the participating clinical sites and the Council of General Practitioners in Sri Lanka • 86% would prescribe it for primary prevention • 93% would prescribe it for secondary prevention • Results did not vary by specialty Soliman et al (Trials 2011).

  17. Polypill acceptabilityUSA physicians Preventive Medicine 2011

  18. Summary • CVD is a major global health issue • A combination of population wide and high risk strategies are required to shift the CVD risk distribution of populations to more optimal levels • There is a call for a paradigm shift from assessment and treatment of risk factors in isolation, to a comprehensive CVD risk assessment and management approach

More Related